Gain Therapeutics Files 8-K
Ticker: GANX · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1819411
| Field | Detail |
|---|---|
| Company | Gain Therapeutics, Inc. (GANX) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Gain Therapeutics dropped an 8-K, check it for financial updates.
AI Summary
Gain Therapeutics, Inc. filed an 8-K on October 14, 2025, to report on Regulation FD disclosures and financial statements. The filing provides information on the company's operations and financial standing as of the reporting date.
Why It Matters
This filing provides crucial updates and disclosures for investors regarding Gain Therapeutics, Inc.'s financial status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing and does not appear to contain any immediately alarming information.
Key Players & Entities
- Gain Therapeutics, Inc. (company) — Registrant
- October 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-40237 (identifier) — Commission File Number
- 85-1726310 (identifier) — IRS Employer Identification No.
- 4800 Montgomery Lane , Suite 220 Bethesda , Maryland 20814 (address) — Principal executive offices
- ( 301 ) 500-1556 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Gain Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD disclosures and financial statements, as indicated by the 'ITEM INFORMATION' section.
On what date is the earliest event reported in this filing?
The earliest event reported in this filing is dated October 14, 2025.
In which U.S. state was Gain Therapeutics, Inc. incorporated?
Gain Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Gain Therapeutics, Inc.?
The principal executive office address is 4800 Montgomery Lane, Suite 220, Bethesda, Maryland 20814.
What is the Commission File Number for Gain Therapeutics, Inc.?
The Commission File Number for Gain Therapeutics, Inc. is 001-40237.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-14 16:56:39
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value GANX The NASDAQ Stock Marke
Filing Documents
- tm2528732d1_8k.htm (8-K) — 25KB
- tm2528732d1_ex99-1.htm (EX-99.1) — 43KB
- tm2528732d1_ex99-1img001.jpg (GRAPHIC) — 79KB
- tm2528732d1_ex99-1img002.jpg (GRAPHIC) — 273KB
- tm2528732d1_ex99-1img003.jpg (GRAPHIC) — 122KB
- tm2528732d1_ex99-1img004.jpg (GRAPHIC) — 100KB
- tm2528732d1_ex99-1img005.jpg (GRAPHIC) — 192KB
- tm2528732d1_ex99-1img006.jpg (GRAPHIC) — 225KB
- tm2528732d1_ex99-1img007.jpg (GRAPHIC) — 128KB
- tm2528732d1_ex99-1img008.jpg (GRAPHIC) — 181KB
- tm2528732d1_ex99-1img009.jpg (GRAPHIC) — 120KB
- tm2528732d1_ex99-1img010.jpg (GRAPHIC) — 140KB
- tm2528732d1_ex99-1img011.jpg (GRAPHIC) — 142KB
- tm2528732d1_ex99-1img012.jpg (GRAPHIC) — 129KB
- tm2528732d1_ex99-1img013.jpg (GRAPHIC) — 91KB
- tm2528732d1_ex99-1img014.jpg (GRAPHIC) — 105KB
- tm2528732d1_ex99-1img015.jpg (GRAPHIC) — 88KB
- tm2528732d1_ex99-1img016.jpg (GRAPHIC) — 134KB
- tm2528732d1_ex99-1img017.jpg (GRAPHIC) — 134KB
- tm2528732d1_ex99-1img018.jpg (GRAPHIC) — 193KB
- tm2528732d1_ex99-1img019.jpg (GRAPHIC) — 121KB
- tm2528732d1_ex99-1img020.jpg (GRAPHIC) — 109KB
- tm2528732d1_ex99-1img021.jpg (GRAPHIC) — 146KB
- tm2528732d1_ex99-1img022.jpg (GRAPHIC) — 115KB
- tm2528732d1_ex99-1img023.jpg (GRAPHIC) — 141KB
- tm2528732d1_ex99-1img024.jpg (GRAPHIC) — 110KB
- tm2528732d1_ex99-1img025.jpg (GRAPHIC) — 102KB
- tm2528732d1_ex99-1img026.jpg (GRAPHIC) — 152KB
- tm2528732d1_ex99-1img027.jpg (GRAPHIC) — 130KB
- tm2528732d1_ex99-1img028.jpg (GRAPHIC) — 161KB
- tm2528732d1_ex99-1img029.jpg (GRAPHIC) — 112KB
- tm2528732d1_ex99-1img030.jpg (GRAPHIC) — 140KB
- tm2528732d1_ex99-1img031.jpg (GRAPHIC) — 115KB
- tm2528732d1_ex99-1img032.jpg (GRAPHIC) — 92KB
- tm2528732d1_ex99-1img033.jpg (GRAPHIC) — 47KB
- 0001104659-25-099343.txt ( ) — 6268KB
- ganx-20251014.xsd (EX-101.SCH) — 3KB
- ganx-20251014_lab.xml (EX-101.LAB) — 33KB
- ganx-20251014_pre.xml (EX-101.PRE) — 22KB
- tm2528732d1_8k_htm.xml (XML) — 4KB
01 Regulation FD
Item 7.01 Regulation FD On October 14, 2025, Gain Therapeutics, Inc. (the "Company") hosted a virtual key opinion leader (KOL) event, " Biomarkers, Clinical Endpoints, and the Path to Disease Modification: Contextualizing the emerging data from GT-02287 " featuring Key Opinion Leaders (KOLs), Karl Kieburtz, M.D., M.P.H., Professor of Neurology, University of Rochester and Kenneth Marek, M.D., President and Senior Scientist, Institute for Neurodegenerative Disorders. The slide presentation presented at the event is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GAIN THERAPEUTICS, INC. Date: October 14, 2025 By: /s/ Gene Mack Name: Gene Mack Title: Chief Executive Officer